High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

ABSTRACT:

Background

High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy.

Methods

Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS).

Results

High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic fac

SUBMITTER: Siesing C 

PROVIDER: S-EPMC5553773 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature